Fuchsjäger-Mayrl G, Wally B, Rainer G, Buehl W, Aggermann T, Kolodjaschna J, Weigert G, Polska E, Eichler H-G, Vass C, Schmetterer L
Department of Clinical Pharmacology, Medical University of Vienna, Austria.
Br J Ophthalmol. 2005 Oct;89(10):1293-7. doi: 10.1136/bjo.2005.067637.
There is evidence that perfusion abnormalities of the optic nerve head are involved in the pathogenesis of glaucoma. There is therefore considerable interest in the effects of topical antiglaucoma drugs on ocular blood flow. A study was undertaken to compare the ocular haemodynamic effects of dorzolamide and timolol in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT).
One hundred and forty patients with POAG or OHT were included in a controlled, randomised, double blind study in two parallel groups; 70 were randomised to receive timolol and 70 to receive dorzolamide for a period of 6 months. Subjects whose intraocular pressure (IOP) did not respond to either of the two drugs were switched to the alternative treatment after 2 weeks. Scanning laser Doppler flowmetry was used to measure blood flow in the temporal neuroretinal rim and the cup of the optic nerve head. Pulsatile choroidal blood flow was assessed using laser interferometric measurement of fundus pulsation amplitude.
Five patients did not respond to timolol and were changed to the dorzolamide group, and 18 patients changed from dorzolamide treatment to timolol. The effects of both drugs on IOP and ocular perfusion pressure were comparable. Dorzolamide, but not timolol, increased blood flow in the temporal neuroretinal rim (8.5 (1.6)%, p<0.001 versus timolol) and the cup of the optic nerve head (13.5 (2.5)%, p<0.001 versus timolol), and fundus pulsation amplitude (8.9 (1.3)%, p<0.001 versus timolol).
This study indicates augmented blood flow in the optic nerve head and choroid after 6 months of treatment with dorzolamide, but not with timolol. It remains to be established whether this effect can help to reduce visual field loss in patients with glaucoma.
有证据表明,视神经乳头灌注异常参与了青光眼的发病机制。因此,局部抗青光眼药物对眼血流的影响备受关注。本研究旨在比较多佐胺和噻吗洛尔对原发性开角型青光眼(POAG)或高眼压症(OHT)患者的眼血流动力学影响。
140例POAG或OHT患者纳入一项对照、随机、双盲研究,分为两个平行组;70例随机接受噻吗洛尔治疗,70例接受多佐胺治疗,为期6个月。眼压(IOP)对两种药物均无反应的受试者在2周后改用另一种治疗。使用扫描激光多普勒血流仪测量颞侧神经视网膜缘和视神经乳头杯盘的血流。使用激光干涉测量眼底搏动幅度评估脉络膜搏动性血流。
5例患者对噻吗洛尔无反应,转而进入多佐胺组,18例患者从多佐胺治疗改为噻吗洛尔治疗。两种药物对IOP和眼灌注压的影响相当。多佐胺增加了颞侧神经视网膜缘(8.5(1.6)%,与噻吗洛尔相比p<0.001)、视神经乳头杯盘(13.5(2.5)%,与噻吗洛尔相比p<0.001)的血流以及眼底搏动幅度(8.9(1.3)%,与噻吗洛尔相比p<0.001),而噻吗洛尔未产生此效果。
本研究表明,多佐胺治疗6个月后,视神经乳头和脉络膜血流增加,而噻吗洛尔无此作用。这种效应是否有助于减少青光眼患者的视野缺损仍有待确定。